GENE ONLINE|News &
Opinion
Blog

2021-08-11| Funding

GentiBio Bags $157 Million in Series A to Fund Development of Treg Cell Therapies

by Rajaneesh K. Gopinath
Share To

A year into its launch, Boston-based startup GentiBio, Inc., which specializes in developing engineered regulatory T cells (Tregs) therapies for immunological diseases, has announced a Series A funding of $157 million.

Led by Matrix Capital Management, the funding round also saw participation from Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children’s Research Institute.

 

Engineered Tregs

Tregs play a key role in preventing autoimmunity and tissue damage in the body. They control immune responses to self as well as foreign antigens and maintain immune homeostasis. However, they are not without limitations.

“Tregs play a vital role in controlling immune responses but are a rare and heterogenous population that is challenging to isolate and purify at scale,” said Adel Nada, M.D., M.S., President, and CEO of GentiBio.

GentiBio is focused on overcoming those limitations by producing engineered Tregs using its novel technology. It intends to precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio licensed its technology from three premier research institutions— Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRI), and Israel-based MIGAL Galilee Research Institute (MIGAL).

“GentiBio engineered Tregs created from abundant autologous and allogeneic T cell sources have the potential to overcome scalability and phenotypic inconsistency issues that are intrinsic to Tregs sorted from peripheral blood,” Adel explained. “With the Series A financing, we are focused on advancing our programs with a uniquely scalable manufacturing process that produces stable and disease-specific engineered Tregs that are also tunable once infused in patients.”

The funds will aid GentiBio to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. The company is currently selecting its T1D candidate and will begin IND-enabling studies before the end of the year.

 

Tregs – A Most Sought After Field

The global market for autoimmune disorder therapies is expected to grow to $90.7 billion by 2024. Recently, several companies have started betting on Tregs. In February, Merck spent $1.85 billion on Pandion Therapeutics to acquire several autoimmune disease therapies, including PT101, which selectively activates and expands Tregs.

Recently, Boston-based Abata Therapeutics secured $95 million in Series A funding led by Third Rock Ventures to accelerate the development of autologous Treg cell therapies for multiple sclerosis and programs in inclusion body myositis and T1D. Last week, Sonoma Biotherapeutics announced an oversubscribed $265 million Series B financing round led by Ally Bridge Group to fund the development of its Treg therapies for T1D and other autoimmune diseases.

It is, therefore, no surprise that funding agencies are queuing up to invest in the booming field of Treg cell therapy.

“We are excited by the (GentiBio’s) preclinical results demonstrating the broad therapeutic potential of its platform to engineer best-in-class Tregs,” said Andy Tran, the incoming Board Director from Matrix Capital Management. “GentiBio’s novel engineering platform has tremendous promise to bring forward durable Treg treatments for a broad array of devastating autoimmune diseases and has the unique ability to scale them cost-effectively for patients.”

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
AbbVie Buys DJS Antibodies For $255 Million To Beef Up Immunology Portfolio
2022-10-21
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
Big Pharma-Backed Capstan Launches With $165 Million To Combine Cell Therapy And mRNA Technology
2022-09-15
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!